芪珠方治疗慢性乙型肝炎的作用机理研究
摘要
背景：慢性乙型病毒性肝炎感染乙型肝炎病毒(HBV)后,机体体液及细胞免疫引起的以肝脏损伤为主的全身性疾病。本病流行范围之广、传播途径之复杂、发病率之高、危害性之大,居各种传染病之首,是严重危害人类生命健康的传染病。慢性乙型肝炎在全球范围内分布,全世界有20多亿人被感染,约3.5亿人成为慢性HBV感染者。慢性乙型肝炎患者中约50%-75%有活跃的病毒复制和肝脏炎症改变,其中10%-20%可发展为肝硬化,1%-5%可演变为肝癌。慢性乙型肝炎是WHO公布的人类疾病死亡原因中第9位的疾病。现代医学主要治疗手段包括保肝、降酶、抗病毒、免疫调节等,有效的抗病毒治疗是根治慢性病毒性肝炎的关键。目标是清除或持续抑制HBV,从而阻止或减轻肝脏的炎症、坏死。大量的临床研究证实抗病毒较为理想的药物是干扰素和核苷类似物。但干扰素适应面窄,副作用明显,远期疗效不理想,价格昂贵。核苷类似物易于产生病毒变异等,其临床应用受到限制。大量的临床和实验研究证实,中药复方在保护肝细胞、调节免疫、抗肝纤维化,进而通过综合作用抑制病毒等方面显示了优越性。但在中医药研究中尚存在不少问题,如迄今中医对慢性乙型肝炎的病因、病机、辨证诊断等方面的认识不统一,与目前国际上普遍采用的以肝组织病理学分级分期、临床表现分型的慢性乙型肝炎诊断标准不相适应,难以准确反应慢性乙型肝炎的病变程度,临床缺乏有效、科学、系统的治疗方法,不能满足慢性乙型病毒性肝炎中医临床的要求。
目的：通过实验研究,探索芪珠方治疗慢性乙型病毒性肝炎作用机理,明确芪珠方药物组成特点,为临床寻找有效的治疗本病的中医药方法奠定基础。
方法：芪珠方是由叶下珠、虎杖、丹参、黄芪,赤芍、白花蛇舌草、土茯苓七味药组成,为保证疗效,最大限度的提出有效成分,本研究选择加热回流法进行提取,通过RP-HPLC对复方中的化学成分进行分析,选择四种不同浓度的乙醇进行提取,分析不同溶剂提取的样品中化学成分的变化。建立肝纤维化模型动物的基础上,中药高、中剂量组分别以16.20g/kg、9.72g/kg(芪珠方生药含量/大鼠体重)灌胃,每日1次,首次造模次日开始给药,连续8周直至动物处死前一天；秋水仙碱组(将秋水仙碱药片磨碎,制成水溶液,每1mL水中含0.1mg秋水仙碱)5.0mL/kg(秋水仙碱含量/大鼠体重)灌胃,每日11次,首次造模次日开始给药,连续8周直至动物处死前一天；模型组用等同于芪珠方大剂量组灌胃体积的生理盐水灌胃,肝组织内TNF-a,IL-4,IL-8,IL-10,TIMP-1,MMP-1,MMP-2,MMP-13表达水平,血清内TIMP-1,MMP-1, MMP-2,MMP-13表达。
结果：不同溶剂提取的芪珠方(70%醇提进样为80μL,其余均为10μL),所得样品出峰数不同,水提及50%、70%、95%提取的复方在25min之前基本上没有出峰,实验过程中,通过加大进样量比较,70%醇提芪珠方出峰最多,且峰形大小和形状较好。肝纤维化模型动物模型组大鼠肝组织中TNF-α,IL-4,IL-8的表达相对空白组明显增加,IL-10的表达则显著减少肝组织中TNF-α,IL-4,IL-8的表达显著减少(P<0.01),IL-10的表达显著增加(P<0.01)；芪珠方高剂量组TNF-α, IL-4,IL-8的表达低于中剂量组,IL-10的表达高于中剂量组；芪珠方水提组IL-4, IL-8, TNF-α的表达低于同剂量乙醇提取组,IL-10的表达高于同剂量乙醇提取组(P<0.01)。与秋水仙碱组相比,芪珠方治疗组的IL-4的表达均高于秋水仙碱组且有显著差异(P<0.01)；芪珠方治疗组IL-8的表达显著高于秋水仙碱组(P<0.01)；芪珠方治疗组IL-10的表达均低于秋水仙碱组且有显著差异(P<0.01)；芪珠方治疗组TNF-α表达均高于秋水仙碱组(P<0.01)。模型组TIMP-1, MMP-2的表达相对高于正常组,MMP-1, MMP-13的表达相对低于正常组,两组相比差异有显著差异(P<0.01)。所有治疗组TIMP-1,MMP-2的表达低于模型组,MMP-1,MMP-13的表达高于模型组,均有显著差异(P<0.01)。芪珠方高剂量组TIMP-1,MMP-2的表达低于中剂量组,MMP-1,MMP-13的表达高于中剂量组,有明显的剂量依赖性(P<0.01)。芪珠方水提组TIMP-1, MMP-2的表达高于同剂量乙醇提取组(P<0.01), MMP-1, MMP-13的表达均低于同剂量乙醇提取组(P<0.01)。与秋水仙碱组相比,芪珠方4组治疗组的TIMP-1的表达均高于秋水仙碱组且有显著差异(P<0.01)；大剂量组的MMP-1表达显著高于秋水仙碱组(P<0.01),中剂量组的表达低于秋水仙碱组,其中醇提中剂量组有差异(P<0.05),水提中剂量组有显著差异(P<0.01)；4组治疗组MMP-2的表达均低于秋水仙碱组,其中复方大剂量组与醇提组大、中剂量3组有显著差异(P<0.01),水提中剂量组无统计学意义(P>0.05)；芪珠方大剂量组MMP-13表达高于秋水仙碱组(P<0.01),中剂量组表达低于秋水仙碱组(P<0.01)。模型组血清TIMP-1, MMP-2的表达相对高于正常组,MMP-1, MMP-13的表达相对低于正常组,两组相比差异有显著差异(P<0.01)。所有治疗组血清TIMP-1,MMP-2的表达低于模型组,MMP-1,MMP-13的表达高于模型组,均有显著差异(P<0.01)。芪珠方高剂量组血清TIMP-1,MMP-2的表达低于中剂量组,MMP-1,MMP-13的表达高于中剂量组,有明显的剂量依赖性(P<0.01)。芪珠方水提组中剂量组血清TIMP-1的表达高于同剂量醇提取中剂量组(P<0.01),高剂量组间无统计学意义(P>0.05)；水提组MMP-1的表达均低于同剂量醇提组(P<0.01)；水提组MMP-2的表达高于同剂量醇提组(P<0.01);MMP-13的表达均低于同剂量乙醇提取组(P<0.01)。与秋水仙碱组相比,芪珠方4组治疗组的TIMP-1的表达均高于秋水仙碱组,水提大、中剂量组和醇提中剂量组有显著差异(P<0.01),醇提大剂量组无统计学意义(P>0.05)；大剂量组的MMP-1表达高于秋水仙碱组(P<0.01),中剂量组的表达低于秋水仙碱组(P<0.01)；4组治疗组MMP-2的表达均低于秋水仙碱组,其中复方大剂量组与醇提组大、中剂量3组有显著差异(P<0.01),水提中剂量组无统计学意义(P>0.05)；芪珠方大剂量组MMP-13表达高于秋水仙碱组(P<0.01),中剂量组表达低于秋水仙碱组(P<0.01)。
结论：芪珠方醇提能够治疗慢性乙型病毒性肝炎及肝纤维化,可能是通过调节肝脏及血清的TNF-a,IL-4,IL-8,IL-10,TIMP-1,MMP-1,MMP-2,MMP-13等发挥作用。
Background:Chronic hepatitis B, hepatitis B virus (HBV) infection, liver damage caused by the humoral and cellular immune systemic disease. The wide range of the epidemic spread of the complexity of ways, the high incidence of the dangers of large, ranking the first of a variety of infectious diseases, and infectious diseases of serious harm to human life and health. Chronic hepatitis B worldwide distribution, more than20million people are infected worldwide, about350million people with chronic HBV infection. About50%-75%of the chronic hepatitis B patients with active viral replication and liver inflammation change, of which10%to20%may develop cirrhosis, and1%to5%may develop into liver cancer. Chronic hepatitis B is a human disease, the cause of death in the WHO announced nine diseases. Modern medical treatment, including the liver, reducing enzyme, antiviral, immunomodulatory, and effective anti-viral therapy cure for chronic viral hepatitis. The goal is to clear or sustained suppression of HBV to prevent or reduce liver inflammation, necrosis. A large number of clinical studies confirmed the ideal antiviral drugs interferon and nucleoside analogues. But interferon adapt narrow obvious side effects, long-term effect is not satisfactory, the price is expensive. Nucleoside analogues are prone to virus mutation, its clinical application is limited. A large number of clinical and experimental studies confirmed that the traditional Chinese medicine to protect liver cells, immune regulation, anti-fibrotic, and then by the combined effects of inhibition of viruses and other shows superiority. Not uniform, but the understanding of the Traditional Chinese Medicine Research surviving many problems, such as the so far Chinese medicine for chronic hepatitis B etiology and pathogenesis, syndrome diagnosis liver histopathological grading and commonly used in the international stage, typing clinical manifestations of chronic hepatitis B diagnostic criteria are incompatible, chronic hepatitis B is difficult to accurately reflect the severity of the clinical treatment of the lack of effective, science, systems can not meet the chronic hepatitis B in Chinese medicine clinical requirements.
Objective:explore stilbene beads side through experimental research, the treatment of chronic hepatitis B mechanism, clear the stilbene beads prescription drug composition characteristics, looking for clinical lay the foundation for effective medicine in the treatment of this disease.
Qizhu decoction side by Phyllanthus, Polygonum cuspidatum, Radix, TPG, diffusa, soil Fuling Qiwei drug composition, the maximum in order to ensure the efficacy of active ingredients, chosen for this study heating reflux extraction by RP-HPLC analysis of the chemical composition of the compound, and choose one of four different concentrations of ethanol extraction and analysis of the changes in the chemical composition of samples of different solvent extraction. Establishment of animal models of liver fibrosis based on traditional Chinese medicine, the middle dose group were16.20g/kg,9.72g/kg (Qi Zhu Fang Sheng the medicine content/rat body weight) orally, once a day, for the first time modeling the administration began the next day, for eight consecutive weeks until the animals were killed the day before; colchicine group (ground, made of an aqueous solution of colchicine tablets per1mL of water containing0.1mg colchicine)5.0mL/kg (colchicine alkali content/rat body weight) orally, once daily, the model for the first time the next day, the administration began eight consecutive weeks until the animals were killed the day before; model group, the same as the the stilbene beads Fangda dose group was given volume of physiological saline gavage, liver tissue TNF-a, IL-4, IL-8, IL-10, TIMP-1, MMP-1, MMP-2, MMP-13expression levels, serum TIMP-1, MMP-1, MMP-2, MMP-13expression.
Results:different solvent extraction stilbene beads side (70%alcohol into the sample to80μL, the rest are10μL) sample obtained a number of peaks, mentioned by50%of water,70%,95%compound extracted basic25min before does not have a peak, during the experiment, by increasing the injection volume comparison,70%ethanolic the stilbene beads side peaks up to the size and shape of the peak shape better. Liver fibrosis model in animal models of rats liver tissue TNF-a, IL-4, IL-8expression relative blank group significantly increased IL-10expression significantly reduced liver tissue TNF-a, IL-4, the expression of IL-8was significantly (P<0.01) reduction in the expression of IL-10's significantly with increased (P<0.01); stilbene beads side high dose group of TNF-a, of IL-4, of IL-8's expression lower than the middle dose group IL-10expression is higher than the middle dose group; the stilbene beads to water extraction group, IL-4, IL-8, TNF-a expression is lower than the same dose of ethanol extract group, IL-10expression is higher than the same dose of ethanol extract group (P<0.01). Expression of IL-4compared to colchicine group, stilbene the beads side treatment group were higher than the colchicine group and there is a significant difference (P<0.01); stilbene beads to treatment group of IL-8expression was significantly higher than in autumn Narcissus alkali group (P<0.01); the stilbene beads to treatment group the expression of IL-10were lower than the colchicine group and a significant difference (P<0.01); the stilbene beads to treatment group were higher than the expression of TNF-a colchicine alkali group (P<0.01). Model group, TIMP-1, MMP-2expression is relatively higher than the normal group, MMP-1, MMP-13expression is relatively lower than the normal group, the two groups differ significant differences (P<0.01). All treatment groups TIMP-1, MMP-2expression is lower than the model group, MMP-1, MMP-13expression is higher than the model group, there were significant differences (P<0.01). Stilbene the beads side high dose group of TIMP-1, MMP-2expression is lower than the middle dose group, MMP-1, MMP-13expression is higher than the middle dose group, significant dose-dependent manner (P<0.01). The stilbene beads to water extraction group, TIMP-1, MMP-2expression is higher than the same dose of ethanol extract group (P<0.01), MMP-1, MMP-13expression were lower than the same dose of ethanol extract group (P<0.01). TIMP-1expression stilbene beads side4treatment groups were higher than the colchicine group compared with the colchicine group, and there is a significant difference (P<0.01); expression of MMP-1in the high-dose group was significantly higher than in autumn Narcissus alkali group (P <0.01), the expression of the middle dose group below the colchicine group in alcohol extract dose group difference (P<0.05) were significantly different (P<0.01), water extraction in the dose group; expression of MMP-2treatment groups were lower than the colchicine group, compound high-dose group and the alcohol extract group, middle dose group, a significant difference (P<0.01), no significant water extraction in the dose group (P>0.05); the stilbene beads Fangda dose group MMP-13expression above the colchicine group (P<0.01), the middle dose group was lower than the colchicine group (P<0.01). Model group, serum of TIMP-1, MMP-2expression is relatively higher than the normal group, MMP-1, MMP-13expression is relatively lower than the normal group, the two groups differ significant differences (P<0.01). All treatment groups serum TIMP-1, MMP-2expression is lower than the model group, MMP-1, MMP-13expression is higher than the model group, there were significant differences (P<0.01). Stilbene the beads side high dose of serum TIMP-1, MMP-2expression is lower than the middle dose group, MMP-1, MMP-13expression is higher than the middle dose group, significant dose-dependent manner (P<0.01). Stilbene beads to water extraction group dose serum TIMP-1expression extract the middle dose group (P<0.01) higher than the same dose of alcohol, the high-dose group was not statistically significant (P>0.05); MMP-1water extract group expression were lower than the same dose of alcohol extract group (P<0.01) higher than the same dose of alcohol extract group (P<0.01); aqueous extract group, the expression of MMP-2; MMP-13expression were lower than the same dose of ethanol extract group (P<0.01). TIMP-1expression compared with colchicine, stilbene beads side4treatment groups were higher than the colchicine group, large water extraction, the middle dose group and the alcohol extract middle dose group were significantly different (P<0.01) alcohol extract high-dose group was not statistically significant (P>0.05); MMP-1expression in the high-dose group than colchicine group (P<0.01), the middle dose group was lower than the colchicine group (P<0.01); expression of MMP-2treatment group were lower than the colchicine group, compound high-dose group and the alcohol extract group, middle dose group, a significant difference (P <0.01), the water was no mention in dose statistically significant (P>0.05); the stilbene beads Fangda dose group MMP-13expression is higher than the colchicine group (P<0.01), the middle dose group was lower than the colchicine group (P<0.01).
Conclusion:Qizhu decoction party alcohol extract to treat chronic hepatitis B and liver fibrosis by regulating the liver and serum TNF-a, IL-4, IL-8, IL-10, TIMP-1, MMP-1, MMP-2, MMP-13.
目的：通过实验研究,探索芪珠方治疗慢性乙型病毒性肝炎作用机理,明确芪珠方药物组成特点,为临床寻找有效的治疗本病的中医药方法奠定基础。
方法：芪珠方是由叶下珠、虎杖、丹参、黄芪,赤芍、白花蛇舌草、土茯苓七味药组成,为保证疗效,最大限度的提出有效成分,本研究选择加热回流法进行提取,通过RP-HPLC对复方中的化学成分进行分析,选择四种不同浓度的乙醇进行提取,分析不同溶剂提取的样品中化学成分的变化。建立肝纤维化模型动物的基础上,中药高、中剂量组分别以16.20g/kg、9.72g/kg(芪珠方生药含量/大鼠体重)灌胃,每日1次,首次造模次日开始给药,连续8周直至动物处死前一天；秋水仙碱组(将秋水仙碱药片磨碎,制成水溶液,每1mL水中含0.1mg秋水仙碱)5.0mL/kg(秋水仙碱含量/大鼠体重)灌胃,每日11次,首次造模次日开始给药,连续8周直至动物处死前一天；模型组用等同于芪珠方大剂量组灌胃体积的生理盐水灌胃,肝组织内TNF-a,IL-4,IL-8,IL-10,TIMP-1,MMP-1,MMP-2,MMP-13表达水平,血清内TIMP-1,MMP-1, MMP-2,MMP-13表达。
结果：不同溶剂提取的芪珠方(70%醇提进样为80μL,其余均为10μL),所得样品出峰数不同,水提及50%、70%、95%提取的复方在25min之前基本上没有出峰,实验过程中,通过加大进样量比较,70%醇提芪珠方出峰最多,且峰形大小和形状较好。肝纤维化模型动物模型组大鼠肝组织中TNF-α,IL-4,IL-8的表达相对空白组明显增加,IL-10的表达则显著减少肝组织中TNF-α,IL-4,IL-8的表达显著减少(P<0.01),IL-10的表达显著增加(P<0.01)；芪珠方高剂量组TNF-α, IL-4,IL-8的表达低于中剂量组,IL-10的表达高于中剂量组；芪珠方水提组IL-4, IL-8, TNF-α的表达低于同剂量乙醇提取组,IL-10的表达高于同剂量乙醇提取组(P<0.01)。与秋水仙碱组相比,芪珠方治疗组的IL-4的表达均高于秋水仙碱组且有显著差异(P<0.01)；芪珠方治疗组IL-8的表达显著高于秋水仙碱组(P<0.01)；芪珠方治疗组IL-10的表达均低于秋水仙碱组且有显著差异(P<0.01)；芪珠方治疗组TNF-α表达均高于秋水仙碱组(P<0.01)。模型组TIMP-1, MMP-2的表达相对高于正常组,MMP-1, MMP-13的表达相对低于正常组,两组相比差异有显著差异(P<0.01)。所有治疗组TIMP-1,MMP-2的表达低于模型组,MMP-1,MMP-13的表达高于模型组,均有显著差异(P<0.01)。芪珠方高剂量组TIMP-1,MMP-2的表达低于中剂量组,MMP-1,MMP-13的表达高于中剂量组,有明显的剂量依赖性(P<0.01)。芪珠方水提组TIMP-1, MMP-2的表达高于同剂量乙醇提取组(P<0.01), MMP-1, MMP-13的表达均低于同剂量乙醇提取组(P<0.01)。与秋水仙碱组相比,芪珠方4组治疗组的TIMP-1的表达均高于秋水仙碱组且有显著差异(P<0.01)；大剂量组的MMP-1表达显著高于秋水仙碱组(P<0.01),中剂量组的表达低于秋水仙碱组,其中醇提中剂量组有差异(P<0.05),水提中剂量组有显著差异(P<0.01)；4组治疗组MMP-2的表达均低于秋水仙碱组,其中复方大剂量组与醇提组大、中剂量3组有显著差异(P<0.01),水提中剂量组无统计学意义(P>0.05)；芪珠方大剂量组MMP-13表达高于秋水仙碱组(P<0.01),中剂量组表达低于秋水仙碱组(P<0.01)。模型组血清TIMP-1, MMP-2的表达相对高于正常组,MMP-1, MMP-13的表达相对低于正常组,两组相比差异有显著差异(P<0.01)。所有治疗组血清TIMP-1,MMP-2的表达低于模型组,MMP-1,MMP-13的表达高于模型组,均有显著差异(P<0.01)。芪珠方高剂量组血清TIMP-1,MMP-2的表达低于中剂量组,MMP-1,MMP-13的表达高于中剂量组,有明显的剂量依赖性(P<0.01)。芪珠方水提组中剂量组血清TIMP-1的表达高于同剂量醇提取中剂量组(P<0.01),高剂量组间无统计学意义(P>0.05)；水提组MMP-1的表达均低于同剂量醇提组(P<0.01)；水提组MMP-2的表达高于同剂量醇提组(P<0.01);MMP-13的表达均低于同剂量乙醇提取组(P<0.01)。与秋水仙碱组相比,芪珠方4组治疗组的TIMP-1的表达均高于秋水仙碱组,水提大、中剂量组和醇提中剂量组有显著差异(P<0.01),醇提大剂量组无统计学意义(P>0.05)；大剂量组的MMP-1表达高于秋水仙碱组(P<0.01),中剂量组的表达低于秋水仙碱组(P<0.01)；4组治疗组MMP-2的表达均低于秋水仙碱组,其中复方大剂量组与醇提组大、中剂量3组有显著差异(P<0.01),水提中剂量组无统计学意义(P>0.05)；芪珠方大剂量组MMP-13表达高于秋水仙碱组(P<0.01),中剂量组表达低于秋水仙碱组(P<0.01)。
结论：芪珠方醇提能够治疗慢性乙型病毒性肝炎及肝纤维化,可能是通过调节肝脏及血清的TNF-a,IL-4,IL-8,IL-10,TIMP-1,MMP-1,MMP-2,MMP-13等发挥作用。
Background:Chronic hepatitis B, hepatitis B virus (HBV) infection, liver damage caused by the humoral and cellular immune systemic disease. The wide range of the epidemic spread of the complexity of ways, the high incidence of the dangers of large, ranking the first of a variety of infectious diseases, and infectious diseases of serious harm to human life and health. Chronic hepatitis B worldwide distribution, more than20million people are infected worldwide, about350million people with chronic HBV infection. About50%-75%of the chronic hepatitis B patients with active viral replication and liver inflammation change, of which10%to20%may develop cirrhosis, and1%to5%may develop into liver cancer. Chronic hepatitis B is a human disease, the cause of death in the WHO announced nine diseases. Modern medical treatment, including the liver, reducing enzyme, antiviral, immunomodulatory, and effective anti-viral therapy cure for chronic viral hepatitis. The goal is to clear or sustained suppression of HBV to prevent or reduce liver inflammation, necrosis. A large number of clinical studies confirmed the ideal antiviral drugs interferon and nucleoside analogues. But interferon adapt narrow obvious side effects, long-term effect is not satisfactory, the price is expensive. Nucleoside analogues are prone to virus mutation, its clinical application is limited. A large number of clinical and experimental studies confirmed that the traditional Chinese medicine to protect liver cells, immune regulation, anti-fibrotic, and then by the combined effects of inhibition of viruses and other shows superiority. Not uniform, but the understanding of the Traditional Chinese Medicine Research surviving many problems, such as the so far Chinese medicine for chronic hepatitis B etiology and pathogenesis, syndrome diagnosis liver histopathological grading and commonly used in the international stage, typing clinical manifestations of chronic hepatitis B diagnostic criteria are incompatible, chronic hepatitis B is difficult to accurately reflect the severity of the clinical treatment of the lack of effective, science, systems can not meet the chronic hepatitis B in Chinese medicine clinical requirements.
Objective:explore stilbene beads side through experimental research, the treatment of chronic hepatitis B mechanism, clear the stilbene beads prescription drug composition characteristics, looking for clinical lay the foundation for effective medicine in the treatment of this disease.
Qizhu decoction side by Phyllanthus, Polygonum cuspidatum, Radix, TPG, diffusa, soil Fuling Qiwei drug composition, the maximum in order to ensure the efficacy of active ingredients, chosen for this study heating reflux extraction by RP-HPLC analysis of the chemical composition of the compound, and choose one of four different concentrations of ethanol extraction and analysis of the changes in the chemical composition of samples of different solvent extraction. Establishment of animal models of liver fibrosis based on traditional Chinese medicine, the middle dose group were16.20g/kg,9.72g/kg (Qi Zhu Fang Sheng the medicine content/rat body weight) orally, once a day, for the first time modeling the administration began the next day, for eight consecutive weeks until the animals were killed the day before; colchicine group (ground, made of an aqueous solution of colchicine tablets per1mL of water containing0.1mg colchicine)5.0mL/kg (colchicine alkali content/rat body weight) orally, once daily, the model for the first time the next day, the administration began eight consecutive weeks until the animals were killed the day before; model group, the same as the the stilbene beads Fangda dose group was given volume of physiological saline gavage, liver tissue TNF-a, IL-4, IL-8, IL-10, TIMP-1, MMP-1, MMP-2, MMP-13expression levels, serum TIMP-1, MMP-1, MMP-2, MMP-13expression.
Results:different solvent extraction stilbene beads side (70%alcohol into the sample to80μL, the rest are10μL) sample obtained a number of peaks, mentioned by50%of water,70%,95%compound extracted basic25min before does not have a peak, during the experiment, by increasing the injection volume comparison,70%ethanolic the stilbene beads side peaks up to the size and shape of the peak shape better. Liver fibrosis model in animal models of rats liver tissue TNF-a, IL-4, IL-8expression relative blank group significantly increased IL-10expression significantly reduced liver tissue TNF-a, IL-4, the expression of IL-8was significantly (P<0.01) reduction in the expression of IL-10's significantly with increased (P<0.01); stilbene beads side high dose group of TNF-a, of IL-4, of IL-8's expression lower than the middle dose group IL-10expression is higher than the middle dose group; the stilbene beads to water extraction group, IL-4, IL-8, TNF-a expression is lower than the same dose of ethanol extract group, IL-10expression is higher than the same dose of ethanol extract group (P<0.01). Expression of IL-4compared to colchicine group, stilbene the beads side treatment group were higher than the colchicine group and there is a significant difference (P<0.01); stilbene beads to treatment group of IL-8expression was significantly higher than in autumn Narcissus alkali group (P<0.01); the stilbene beads to treatment group the expression of IL-10were lower than the colchicine group and a significant difference (P<0.01); the stilbene beads to treatment group were higher than the expression of TNF-a colchicine alkali group (P<0.01). Model group, TIMP-1, MMP-2expression is relatively higher than the normal group, MMP-1, MMP-13expression is relatively lower than the normal group, the two groups differ significant differences (P<0.01). All treatment groups TIMP-1, MMP-2expression is lower than the model group, MMP-1, MMP-13expression is higher than the model group, there were significant differences (P<0.01). Stilbene the beads side high dose group of TIMP-1, MMP-2expression is lower than the middle dose group, MMP-1, MMP-13expression is higher than the middle dose group, significant dose-dependent manner (P<0.01). The stilbene beads to water extraction group, TIMP-1, MMP-2expression is higher than the same dose of ethanol extract group (P<0.01), MMP-1, MMP-13expression were lower than the same dose of ethanol extract group (P<0.01). TIMP-1expression stilbene beads side4treatment groups were higher than the colchicine group compared with the colchicine group, and there is a significant difference (P<0.01); expression of MMP-1in the high-dose group was significantly higher than in autumn Narcissus alkali group (P <0.01), the expression of the middle dose group below the colchicine group in alcohol extract dose group difference (P<0.05) were significantly different (P<0.01), water extraction in the dose group; expression of MMP-2treatment groups were lower than the colchicine group, compound high-dose group and the alcohol extract group, middle dose group, a significant difference (P<0.01), no significant water extraction in the dose group (P>0.05); the stilbene beads Fangda dose group MMP-13expression above the colchicine group (P<0.01), the middle dose group was lower than the colchicine group (P<0.01). Model group, serum of TIMP-1, MMP-2expression is relatively higher than the normal group, MMP-1, MMP-13expression is relatively lower than the normal group, the two groups differ significant differences (P<0.01). All treatment groups serum TIMP-1, MMP-2expression is lower than the model group, MMP-1, MMP-13expression is higher than the model group, there were significant differences (P<0.01). Stilbene the beads side high dose of serum TIMP-1, MMP-2expression is lower than the middle dose group, MMP-1, MMP-13expression is higher than the middle dose group, significant dose-dependent manner (P<0.01). Stilbene beads to water extraction group dose serum TIMP-1expression extract the middle dose group (P<0.01) higher than the same dose of alcohol, the high-dose group was not statistically significant (P>0.05); MMP-1water extract group expression were lower than the same dose of alcohol extract group (P<0.01) higher than the same dose of alcohol extract group (P<0.01); aqueous extract group, the expression of MMP-2; MMP-13expression were lower than the same dose of ethanol extract group (P<0.01). TIMP-1expression compared with colchicine, stilbene beads side4treatment groups were higher than the colchicine group, large water extraction, the middle dose group and the alcohol extract middle dose group were significantly different (P<0.01) alcohol extract high-dose group was not statistically significant (P>0.05); MMP-1expression in the high-dose group than colchicine group (P<0.01), the middle dose group was lower than the colchicine group (P<0.01); expression of MMP-2treatment group were lower than the colchicine group, compound high-dose group and the alcohol extract group, middle dose group, a significant difference (P <0.01), the water was no mention in dose statistically significant (P>0.05); the stilbene beads Fangda dose group MMP-13expression is higher than the colchicine group (P<0.01), the middle dose group was lower than the colchicine group (P<0.01).
Conclusion:Qizhu decoction party alcohol extract to treat chronic hepatitis B and liver fibrosis by regulating the liver and serum TNF-a, IL-4, IL-8, IL-10, TIMP-1, MMP-1, MMP-2, MMP-13.
引文
[1]赵海明.辨证治疗慢性乙型肝炎.浙江中西医结合杂志,2002,12(9)：584
[2]张振榆,牛丽萍.乙肝平治疗慢性乙型肝炎200例.陕西中医,2003,24(1)：30-31
[3]潘利民.辨证治疗慢性乙型肝炎100例.陕西中医,1996,17(7)：292
[4]谌宁生.辨证分型论治慢性乙型肝炎166例临床分析.中国医药学报,1992,7(1)：29
[5]薛焕德,刘晓艳,等.中医辨证治疗慢性活动性乙型肝炎80例临床观察.中医杂志,1998,39(8)：476-478
[6]张玮,王育群,等.乙肝清热解毒合养阴活血冲剂治疗乙肝的临床和实验研究.辽宁中医杂志,2002,29(5)：269-270
[7]刘如秀.辨证分型治疗慢性乙型肝炎36例.湖南中医杂志,2000,16(3)：34-35
[8]白新.桃红四物汤治疗慢性活动性肝炎60例.陕西中医,1996,17(7)：294
[9]冯圣平.自拟健脾益肾解毒活血汤治疗慢性乙肝56例.四川中医,2002,20(9)：45
[10]徐立明.“黄芪解毒活血汤”治疗慢性乙肝107例.江苏中医,2000,21(10)：22-23
[11]罗永,王维强,等.中医药辨治乙肝病毒携带者118例.新中医,1999,31(11)：40
[12]蔡行平.以淡附子为主治疗慢性乙型肝炎35例.湖南中医杂志,2002,18(1)：30
[13]黄象安,姜良铎,等.扶正健肝口服液治疗慢性乙型肝炎32例.中西医结合肝病杂志,2002,12(2)：106
[14]胡文豪.“祛毒益肝方”对HBV相关血清标志物转阴的疗效观察.上海中医药杂志,1999,(8)：10
[15]阮孝廉.强肝解毒汤治疗乙型肝炎132例临床观察.新中医,1998,30(1)：42
[16]郑翔,张压西,等.益肝养阴丸治疗慢性乙型病毒性肝炎102例.中西医结合肝病杂志,2003,13(4)：231-232
[17]张惠芸,李增奎,等.治肝灵合肝得健治疗慢性乙型肝炎疗效观察.辽宁中医杂志,2002,29(10)：602-603
[18]陈民佶,邢练军等.活血解毒补肾为主治疗100例慢性乙型病毒肝炎临床观察.上海中医药杂,1997,(1)：28-29
[19]巫善明.病毒性肝炎丙氨酸转氨酶持续升高的对策.新医学.1996,27(9)：457-458
[20]孙朋强,伊丽利.小柴胡汤加味治疗慢性乙型肝炎72例[J].山东中医杂志,2000,19(9)：536.
[21]孙兰,朱晓勇,李庆勇.中药配方颗粒制备小柴胡汤的药效研究[J].中药药理与临床,2004,2(20)：4.
[22]王京奇,李永泉,李登福.扶正疏泄法治疗慢性乙肝96例[J].北京中医,2002,21(3)：154.
[23]苗祥东.当归愈肝散治疗慢性乙肝的临床观察.辽宁中医杂志,2003,30(1)：32-33
[24]张玮,王育群,等.乙肝清热解毒合养阴活血冲剂治疗乙肝的临床和实验研究.辽宁中医杂志,2002,29(5)：269-270
[25]许佳平,白宪光.双甲五灵胶囊治疗慢性乙型肝炎50例.安徽中医学院学报,2002,21(1)：18
[26]黄象安,姜良铎,等.扶正健肝口服液治疗慢性乙型肝炎32例.中西医结合肝病杂志,2002,12(2)：106
[27]郝丽萍,张瑞梅.五灵丸治疗慢性乙型病毒性肝炎疗效观察.中成药,1997,19(8)：24-26
[28]喻森山,安京亚,等.8868口服液对乙型肝炎病毒血清标志物某些指标的影响.中医杂志,1993,34(5)：283
[29]姚桂树,王玉贤,等.复肝宁治疗慢性乙型病毒性肝炎临床研究.中医药学报,2004,32(4)：11-12
[30]郑翔,张压西,等.益肝养阴丸治疗慢性乙型病毒性肝炎102例.中西医结合肝病杂志,2003,13(4)：231-232
[31]黄顺东,熊昌清,等.苦参碱注射液治疗慢性乙型肝炎34例.中西医结合肝病杂志,2003,13(3)：147
[32]吴勤,唐善令.冬虫夏草治疗慢性肝病的研究进展.中西医结合肝病杂志,1997,7(1)：57-59
[33]陈民佶,邢练军等.活血解毒补肾为主治疗100例慢性乙型病毒肝炎临床观察.上海中医药杂,1997,(1)：28-29
[34]巫善明.病毒性肝炎丙氨酸转氨酶持续升高的对策.新医学.1996,27(9)：457-458
[35]丁民谋,巫协宁,等.红宝清除慢性乙型肝患者血清HBV DNA和e抗原的远期疗效.中西医结合肝病杂志,1995,5(1)：18-20
[36]王辉,卢秉久.大黄在肝病治疗中的应用举隅.辽宁中医学院学报,2004,6(1)：32-33
[37]刘克洲,顾亚仙.复方黄芪治疗慢性乙型肝炎的临床及实验研究.中国中西医结合杂志,1996,16(7)：394-397
[38]黄象安,姜良铎,等.扶正健肝口服液治疗慢性乙型肝炎32例.中西医结合肝病杂志,2002,12(2)：106
[39]Sato H,Goto W.Yamamura J,et al. Therapeutic basis of glycyrrhizin on chronic hepatitis B[J].Antiviral Res,1996,30(2-3):171.
[40]邱德凯,张泳.冬虫夏草糖脂质体治疗慢性乙型肝炎的研究.中华消化杂志,1991,11(2)：69-72
[41]郑民实,郑有方.1000种中草药抑制乙型肝炎病毒表面抗原的实验研究.中医杂志,1989,30(11)：47-48
[42]刘克洲,顾亚仙.复方黄芪治疗慢性乙型肝炎的临床及实验研究.中国中西医结合杂志,1996,16(7)：394-397
[43]邱德凯,张泳.冬虫夏草糖脂质体治疗慢性乙型肝炎的研究.中华消化杂志,1991,11(2)：69-72
[44]程明亮,等.肝纤维化的基础研究及临床.北京：人民卫生出版社,1996,231-249
[45]刘成,姜春萌,刘成海,等.扶正化瘀方对肝星状细胞分泌血管内皮生长因子的干预[J].中华肝脏病杂志,2001,9(5)：282
[46]叶峰,刘呋,等.不同剂量丹参注射液治疗肝硬化的临床研究.中药材,2005,28(9)：850-853
[47]洪嘉禾,等.实用中医肝病学.上海：上海中医药大学出版社,1993,787-791
[48]田庚元,冯宇澄.植物多糖的研究进展.中国中药杂志,1995,20(7)：441-444
[49]于淑琴,阎淑新.云芝多糖对慢性乙肝的疗效观察.辽宁药物与临床,1999,2(3)：12-13
[50]李文.中草药抑制HBV-DNA的实验研究.中医杂志,1997.38(1)：46-47
[51]程良斌.香菇多糖的作用机理及临床应用.中西医结合肝病杂志,1997,7(1)：59-62
[52]刘庄.复方华蟾素口服液抗乙肝病毒体外实验研究.中国中西医结合杂志,1996,6(4)：14-15
[53]Venkateswaran pSi Millman I,Blumberg BS.Effects of an extract from Phyllanthus niruri of hepatitis B and woodchuck hepatitis viruses:In vitro and in vivo studies.proc Natl Acad sci USA,1987,84(1):274
[54]Thyagarajan SP, Subramanian S, ThiruNalasundari T, etaL.Effect of Phyllanthus amarus on chronic carries of hepatitis B virus.Lancet,1988,2 (8614):764.
[55]李彩东,吴斌,等.苦味叶下珠胶囊的制备与临床应用.中国医院药学杂志,2005,25(8)：771-772
[56]黄昆明.叶下珠治疗慢性乙型肝炎38例.中医药信息,1999;(6)：32
[57]李庚元,等.复方叶下珠胶囊治疗乙肝38例.中西医结合肝病杂志.1999,9(1)：32
[58]韩扬,陈力,等.肝炎灵穴位治疗慢性乙型肝炎的临床研究.中西医结合肝病杂志,2002,12(5)：274-275
[59]李烨,王新华,等.混血穴位注射疗法治疗慢性乙型肝炎54例.中西医结合肝病杂志,2003,13(4)：200-201
[60]Nakao k Nakata k, Yamashita M, et al.p48(ISGF 3gamma) is involved interferorr alphainduced suppression of hepatits B virus enhancer lactivty.J Biol Chem,1999,274(40):28075
[61]黄以群,王崇国,李树清,等.干扰素α抗肝纤维化的实验研究.中华肝脏病杂志,2002,10(1)：71
[62]Erhardt A,Blondin D,Hauck K, Sagir A et al.Response to interferon alfa is hepatitis B virus genotype dependent:genotype A is more sensitive to interferon than genotype D.Gut.2005,54(7):1009-1013
[63]Lau GK,Piratvisuth T,Luo KX, Marcellin P. Peginterferon Alfa-2a, lamivudine,and the combination for HBeAg-posirive chronic hepatitis B.N Ensl J Med.2005,352(26):2682-2695
[64]秦成勇,孟宪国.拉米夫定与YMDD变异.山东医药,2003,43：56-56
[65]Bemasconi E,Battegay M, Lai C L, et al.Lamivudine for Chronic Hepatitis B.New England Journal of Medicine,1998,339(24):1786
[66]Ying C, De Clercq E, Neyts J.Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. Journal of Viral Hepatitis,2000,7:79-83
[67]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B.New England Journal of Medicine,2003,348:808-816
[68]Dando T, Plosker G. Adefovir dipivoxil:a review of its use in chronic hepatitis B. Drugs,2003,63: 2215-2234
[69]Baker DE. Adefovir dipivoxil:focus on its use in the treatment of chronic hepatitis B.Rev Gastroenterol Disord,2005,5(2):89-100
[70]蒋华,徐智儒,张晓青.阿德福韦酯药动学研究进展.中国药学杂志,2005,40(1)：6-10
[71]Lai CL,Rosmawati M, Lao J,et al.Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.Gastroenterology,2002,123(6):1831-1838
[72]Mutchnick MG, Lindsay KL, Schiff ER, et al.Thymosin al treatment of chronic hepatitis B.Journal of Viral Hepatitis,2000,6:397-403
[73]Maryline Mancini-Bourgine,Helene Fontaine,Daniel Scott-Algara,et al.Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.Journal of Hepatology,2004, 40:874-882
[74]中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南[J].国际流行病学传染病学杂志,2006,33：2.
[75]Jay H. Hoofnagle Hepatitis B-preventable and now treatable[J].N Engl J Med,2006,354:1074.
[76]顾婧菡,卓超,闫丽.抗乙型肝炎病毒药物的研究进展[J].国外医学药学分册,2007,34(2)：110.
[77][25]曾卫新.谭荣欣.尹燕耀.派罗欣治疗慢性乙肝18例临床观察[J].实用临床医学,2005,6(12)：36.
[78]MARCELL IN P,MOMMEJA MAR IN H,SECKS SL,et al. A phase II dose esealatine trial of clevudine in patients with chronic hepatitis B [J].Hepatology,2004,40(1):140.
[79]季游.核苷类抗乙肝病毒药物的研究进展[J].中国药师,2006,9(11)：1054.
[80]ROMERO M R,MARTLNEZ-D IEZ M C,LARENA M G,et al. Evidence for dual effects of DNA -reactive bile acid derivatiyes(Bamets) on hepatitis B virus life cycle in an in vitro rep locative system[J]. Antivir Chem Chem other,2002,13(6):371.
[81]DANDO T M, WAGSTAFF A J. Emtricitabine/tenofovir disop roxil fumarate[J]. Drugs,2004,64(18):2075.
[82]舒欣,李刚,姚集鲁.拉米夫定治疗乙型肝炎耐药性的产生及YMDD变异的研究[J].国外医学内科学分册,2000,27(7)：302.
[83]LAI C L.EUNG N W Y.TEO E K,et al. Results of a one-yearinternational phase II B comparative trial of telbivudine,lamivudine,and the combination,in patients with chronic hepatitis B [J].Hepatology,2003,38 (Suppl 1):262A.
[84]蔡军,熊玉卿.抗乙型肝炎病毒创新药物的研究进展[J].医药导报2009,28(1)：86.
[85]HADZIYANN IS S J.TASSOPOULOS N C,HEATHCOTE E J,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology,2006,131(6):1743.
[86]Liu P,Hu YY,Liu C H,et al. Effects of salvianolic acid A (SA-A) on liver injury:SA-A action of hepatic peroxidation [J].Liver,2001,21:384.
[87]TEMNNEY D J.Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase [J].Hepatology,2004,40(4Supp 111):245A.
[88]QAQ ISH R B, MARRES K A, R ITCH IE D J. Adefovir dip ivoxil:a new antiviral agent for the treatment of hepatitis B virus infection[J].Clin Ther,2003,25(12):3084.
[1]袁永兵,张兰珍,郭亚建,等.RP-HPLC法测定叶下珠中没食子酸、柯里拉京和鞣花酸的含量[J].北京中医药大学学报,2009,32(1)：56-58.
[2]彭立志,贺劲松,童光东,等.叶下珠提取物抗乙肝病毒及乙肝病毒X基因的研究[J].中西医结合肝病杂志,2006,16(6)：340-343.
[3]谢志春.叶下珠抗乙肝病毒作用的研究现状[J].广西医学,2006,28(2)：164-166.
[4]张芝英.高效液相色谱法测定叶下珠中没食子酸的含量[J].中国药业,2002,11(7)：53.
[5]李家珉.叶下珠中抗PA1-1成分柯里拉京的提取分离[D].广州中医药大学,2009,广州.
[6]沈志强,陈蓬,段理,等.叶下珠有效部位对凝血系统的影响[J].中草药,2004,35(5)：539-542.
[7]窦志芳,冯前进,闫娟丽,等.苦味叶下珠抗病毒作用的研究进展[J].中华中医药期刊,2007,25(11)：2311-2312.
[8]李兰岚,范适,饶立群,等.叶下珠提取物对体外四氯化碳损伤肝细胞的保护作用[J].中国组织工程与临床康复,2007,11(25)：4909-4912.
[9]冀德富,郭冬艳,裴妙荣.叶下珠总多酚提取工艺的优选[J].山西中医学院学报,2010,11(1)：16-18.
[10]肖凯,宣利江,徐亚明,等.虎杖的化学成分研究[J].中国药学杂志,2003,38(1)：12-15.
[11]莫志贤,邵红霞.白藜芦醇苷体外对过氧化氢导致小鼠肝细胞损伤的保护作用[J].中国药理学通报,2000,16(5)：519-521.
[12]张霖,陈育尧,孙学刚,等.虎杖苷对非酒精性脂肪肝大鼠保护作用及机制研究[J].陕西中医,2010,31(6)：756-758.
[13]杨溪琳.虎杖的现代药用研究[J].中国社区医师,2008,10(1)：24.
[14]陈文霞,谈献和,李伟,等.白花蛇舌草]-IPLC指纹图谱的研究[J].现代中药研究与实践,2006,20：38-40.
[15]谭宁华,王双明,杨亚滨,等.白花蛇舌草抗肿瘤活性和初化学研究[J].天然产物研究与开发,2004,14(5)：33-36.
[16]赵浩如,李瑞,林以宁,等.白花蛇舌草不同提取工艺对抗肿瘤活性的影响[J].中国药科大学学报,2002,33(6)：510.
[17]张硕,宋衍芹,倪同尚,等.白花蛇舌草总黄酮抑制人肝癌细胞的靶基因调控[J].世界华人消化杂志,2007,15(10)：1060-1066.
[18]陈秀珍,朱大诚,王艳辉.白花蛇舌草药理作用及临床应用研究进展[J].中药材,2009,32(1)：157-160.
[19]阮金兰,赵钟样,曾庆忠.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19 (9)：965-970.
[20]陈晓宇,宗云奎.三种中草药及其复方体外对HBsAg、HBeAg分泌的抑制[J].中国药物与临床,2002,2(1)：46-48.
[21]黄桢.黄芪多糖的药理研究进展[J].中国临床医药学杂志,2002,11(5)：315.
[22]王淑华,王红霞.浅析黄芪不同剂量的药理作用[J].浙江中医杂志,2002(6)：260.
[23]侯双,杨艳芳,魏建和,等.丹参有效成分合成积累及调控的分子机制研究进展[J].现代中药研究与实践,2010,24(4)：82-85.
[24]刘艾林,李铭源,王一涛,等.丹参药理学活性物质基础研究现状[J].中国药学杂志,2007,42(9)：641-646.
[25]辜海英,钟森,陈红苹.复方丹参注射液治疗慢性乙型肝炎的荟萃分析[J].现代中西医结合杂志,2009,18(16)：1851.
[26]沙飞,禹志领,王一涛.土茯苓品质与药理研究进展[J].中药材,2006,29(5)：516-519.
[27]曾惠芳,苏子仁,史俏蓉,等.虎杖单煎、复方共煎过程中的物理化学变化初探[J].中国药房,1999,10(3)：112-113.
[28]苏子仁,曾惠芳,史俏蓉.虎杖提取工艺初探[J].中国实验方剂学杂志,1998,24(11)：671.
[29]陆汉军,白凝凝.虎杖解毒汤治疗急性乙型病毒性肝炎128例[J].辽宁中医杂志,2001,28(7)：415.
[30]艾绍佐.以虎杖为主治甲型肝炎初探[J].中国民族民间医药杂志,2002,58：273.
[31]王志洁,程仲敏,方学韫.虎杖、黄芪联用抗I型疱疹病毒药效分析[J].中国中药杂志,1999,24(3)：176-181.
[32]陈英利,刑杰,吕跃山,等.黄芪、赤芍对小鼠免疫性肝损伤的保护作用[J].贵阳医学院学报,2008,33(4)：357-359.
[33]黄浩,周琳,姜标.丹参-赤芍配伍的化学成分动态变化研究[J].世界科学技术-中医药现代化·基础研究,2005,7(4)：18-23.
[2]张振榆,牛丽萍.乙肝平治疗慢性乙型肝炎200例.陕西中医,2003,24(1)：30-31
[3]潘利民.辨证治疗慢性乙型肝炎100例.陕西中医,1996,17(7)：292
[4]谌宁生.辨证分型论治慢性乙型肝炎166例临床分析.中国医药学报,1992,7(1)：29
[5]薛焕德,刘晓艳,等.中医辨证治疗慢性活动性乙型肝炎80例临床观察.中医杂志,1998,39(8)：476-478
[6]张玮,王育群,等.乙肝清热解毒合养阴活血冲剂治疗乙肝的临床和实验研究.辽宁中医杂志,2002,29(5)：269-270
[7]刘如秀.辨证分型治疗慢性乙型肝炎36例.湖南中医杂志,2000,16(3)：34-35
[8]白新.桃红四物汤治疗慢性活动性肝炎60例.陕西中医,1996,17(7)：294
[9]冯圣平.自拟健脾益肾解毒活血汤治疗慢性乙肝56例.四川中医,2002,20(9)：45
[10]徐立明.“黄芪解毒活血汤”治疗慢性乙肝107例.江苏中医,2000,21(10)：22-23
[11]罗永,王维强,等.中医药辨治乙肝病毒携带者118例.新中医,1999,31(11)：40
[12]蔡行平.以淡附子为主治疗慢性乙型肝炎35例.湖南中医杂志,2002,18(1)：30
[13]黄象安,姜良铎,等.扶正健肝口服液治疗慢性乙型肝炎32例.中西医结合肝病杂志,2002,12(2)：106
[14]胡文豪.“祛毒益肝方”对HBV相关血清标志物转阴的疗效观察.上海中医药杂志,1999,(8)：10
[15]阮孝廉.强肝解毒汤治疗乙型肝炎132例临床观察.新中医,1998,30(1)：42
[16]郑翔,张压西,等.益肝养阴丸治疗慢性乙型病毒性肝炎102例.中西医结合肝病杂志,2003,13(4)：231-232
[17]张惠芸,李增奎,等.治肝灵合肝得健治疗慢性乙型肝炎疗效观察.辽宁中医杂志,2002,29(10)：602-603
[18]陈民佶,邢练军等.活血解毒补肾为主治疗100例慢性乙型病毒肝炎临床观察.上海中医药杂,1997,(1)：28-29
[19]巫善明.病毒性肝炎丙氨酸转氨酶持续升高的对策.新医学.1996,27(9)：457-458
[20]孙朋强,伊丽利.小柴胡汤加味治疗慢性乙型肝炎72例[J].山东中医杂志,2000,19(9)：536.
[21]孙兰,朱晓勇,李庆勇.中药配方颗粒制备小柴胡汤的药效研究[J].中药药理与临床,2004,2(20)：4.
[22]王京奇,李永泉,李登福.扶正疏泄法治疗慢性乙肝96例[J].北京中医,2002,21(3)：154.
[23]苗祥东.当归愈肝散治疗慢性乙肝的临床观察.辽宁中医杂志,2003,30(1)：32-33
[24]张玮,王育群,等.乙肝清热解毒合养阴活血冲剂治疗乙肝的临床和实验研究.辽宁中医杂志,2002,29(5)：269-270
[25]许佳平,白宪光.双甲五灵胶囊治疗慢性乙型肝炎50例.安徽中医学院学报,2002,21(1)：18
[26]黄象安,姜良铎,等.扶正健肝口服液治疗慢性乙型肝炎32例.中西医结合肝病杂志,2002,12(2)：106
[27]郝丽萍,张瑞梅.五灵丸治疗慢性乙型病毒性肝炎疗效观察.中成药,1997,19(8)：24-26
[28]喻森山,安京亚,等.8868口服液对乙型肝炎病毒血清标志物某些指标的影响.中医杂志,1993,34(5)：283
[29]姚桂树,王玉贤,等.复肝宁治疗慢性乙型病毒性肝炎临床研究.中医药学报,2004,32(4)：11-12
[30]郑翔,张压西,等.益肝养阴丸治疗慢性乙型病毒性肝炎102例.中西医结合肝病杂志,2003,13(4)：231-232
[31]黄顺东,熊昌清,等.苦参碱注射液治疗慢性乙型肝炎34例.中西医结合肝病杂志,2003,13(3)：147
[32]吴勤,唐善令.冬虫夏草治疗慢性肝病的研究进展.中西医结合肝病杂志,1997,7(1)：57-59
[33]陈民佶,邢练军等.活血解毒补肾为主治疗100例慢性乙型病毒肝炎临床观察.上海中医药杂,1997,(1)：28-29
[34]巫善明.病毒性肝炎丙氨酸转氨酶持续升高的对策.新医学.1996,27(9)：457-458
[35]丁民谋,巫协宁,等.红宝清除慢性乙型肝患者血清HBV DNA和e抗原的远期疗效.中西医结合肝病杂志,1995,5(1)：18-20
[36]王辉,卢秉久.大黄在肝病治疗中的应用举隅.辽宁中医学院学报,2004,6(1)：32-33
[37]刘克洲,顾亚仙.复方黄芪治疗慢性乙型肝炎的临床及实验研究.中国中西医结合杂志,1996,16(7)：394-397
[38]黄象安,姜良铎,等.扶正健肝口服液治疗慢性乙型肝炎32例.中西医结合肝病杂志,2002,12(2)：106
[39]Sato H,Goto W.Yamamura J,et al. Therapeutic basis of glycyrrhizin on chronic hepatitis B[J].Antiviral Res,1996,30(2-3):171.
[40]邱德凯,张泳.冬虫夏草糖脂质体治疗慢性乙型肝炎的研究.中华消化杂志,1991,11(2)：69-72
[41]郑民实,郑有方.1000种中草药抑制乙型肝炎病毒表面抗原的实验研究.中医杂志,1989,30(11)：47-48
[42]刘克洲,顾亚仙.复方黄芪治疗慢性乙型肝炎的临床及实验研究.中国中西医结合杂志,1996,16(7)：394-397
[43]邱德凯,张泳.冬虫夏草糖脂质体治疗慢性乙型肝炎的研究.中华消化杂志,1991,11(2)：69-72
[44]程明亮,等.肝纤维化的基础研究及临床.北京：人民卫生出版社,1996,231-249
[45]刘成,姜春萌,刘成海,等.扶正化瘀方对肝星状细胞分泌血管内皮生长因子的干预[J].中华肝脏病杂志,2001,9(5)：282
[46]叶峰,刘呋,等.不同剂量丹参注射液治疗肝硬化的临床研究.中药材,2005,28(9)：850-853
[47]洪嘉禾,等.实用中医肝病学.上海：上海中医药大学出版社,1993,787-791
[48]田庚元,冯宇澄.植物多糖的研究进展.中国中药杂志,1995,20(7)：441-444
[49]于淑琴,阎淑新.云芝多糖对慢性乙肝的疗效观察.辽宁药物与临床,1999,2(3)：12-13
[50]李文.中草药抑制HBV-DNA的实验研究.中医杂志,1997.38(1)：46-47
[51]程良斌.香菇多糖的作用机理及临床应用.中西医结合肝病杂志,1997,7(1)：59-62
[52]刘庄.复方华蟾素口服液抗乙肝病毒体外实验研究.中国中西医结合杂志,1996,6(4)：14-15
[53]Venkateswaran pSi Millman I,Blumberg BS.Effects of an extract from Phyllanthus niruri of hepatitis B and woodchuck hepatitis viruses:In vitro and in vivo studies.proc Natl Acad sci USA,1987,84(1):274
[54]Thyagarajan SP, Subramanian S, ThiruNalasundari T, etaL.Effect of Phyllanthus amarus on chronic carries of hepatitis B virus.Lancet,1988,2 (8614):764.
[55]李彩东,吴斌,等.苦味叶下珠胶囊的制备与临床应用.中国医院药学杂志,2005,25(8)：771-772
[56]黄昆明.叶下珠治疗慢性乙型肝炎38例.中医药信息,1999;(6)：32
[57]李庚元,等.复方叶下珠胶囊治疗乙肝38例.中西医结合肝病杂志.1999,9(1)：32
[58]韩扬,陈力,等.肝炎灵穴位治疗慢性乙型肝炎的临床研究.中西医结合肝病杂志,2002,12(5)：274-275
[59]李烨,王新华,等.混血穴位注射疗法治疗慢性乙型肝炎54例.中西医结合肝病杂志,2003,13(4)：200-201
[60]Nakao k Nakata k, Yamashita M, et al.p48(ISGF 3gamma) is involved interferorr alphainduced suppression of hepatits B virus enhancer lactivty.J Biol Chem,1999,274(40):28075
[61]黄以群,王崇国,李树清,等.干扰素α抗肝纤维化的实验研究.中华肝脏病杂志,2002,10(1)：71
[62]Erhardt A,Blondin D,Hauck K, Sagir A et al.Response to interferon alfa is hepatitis B virus genotype dependent:genotype A is more sensitive to interferon than genotype D.Gut.2005,54(7):1009-1013
[63]Lau GK,Piratvisuth T,Luo KX, Marcellin P. Peginterferon Alfa-2a, lamivudine,and the combination for HBeAg-posirive chronic hepatitis B.N Ensl J Med.2005,352(26):2682-2695
[64]秦成勇,孟宪国.拉米夫定与YMDD变异.山东医药,2003,43：56-56
[65]Bemasconi E,Battegay M, Lai C L, et al.Lamivudine for Chronic Hepatitis B.New England Journal of Medicine,1998,339(24):1786
[66]Ying C, De Clercq E, Neyts J.Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. Journal of Viral Hepatitis,2000,7:79-83
[67]Marcellin P, Chang TT, Lim SG, et al.Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B.New England Journal of Medicine,2003,348:808-816
[68]Dando T, Plosker G. Adefovir dipivoxil:a review of its use in chronic hepatitis B. Drugs,2003,63: 2215-2234
[69]Baker DE. Adefovir dipivoxil:focus on its use in the treatment of chronic hepatitis B.Rev Gastroenterol Disord,2005,5(2):89-100
[70]蒋华,徐智儒,张晓青.阿德福韦酯药动学研究进展.中国药学杂志,2005,40(1)：6-10
[71]Lai CL,Rosmawati M, Lao J,et al.Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.Gastroenterology,2002,123(6):1831-1838
[72]Mutchnick MG, Lindsay KL, Schiff ER, et al.Thymosin al treatment of chronic hepatitis B.Journal of Viral Hepatitis,2000,6:397-403
[73]Maryline Mancini-Bourgine,Helene Fontaine,Daniel Scott-Algara,et al.Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers.Journal of Hepatology,2004, 40:874-882
[74]中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南[J].国际流行病学传染病学杂志,2006,33：2.
[75]Jay H. Hoofnagle Hepatitis B-preventable and now treatable[J].N Engl J Med,2006,354:1074.
[76]顾婧菡,卓超,闫丽.抗乙型肝炎病毒药物的研究进展[J].国外医学药学分册,2007,34(2)：110.
[77][25]曾卫新.谭荣欣.尹燕耀.派罗欣治疗慢性乙肝18例临床观察[J].实用临床医学,2005,6(12)：36.
[78]MARCELL IN P,MOMMEJA MAR IN H,SECKS SL,et al. A phase II dose esealatine trial of clevudine in patients with chronic hepatitis B [J].Hepatology,2004,40(1):140.
[79]季游.核苷类抗乙肝病毒药物的研究进展[J].中国药师,2006,9(11)：1054.
[80]ROMERO M R,MARTLNEZ-D IEZ M C,LARENA M G,et al. Evidence for dual effects of DNA -reactive bile acid derivatiyes(Bamets) on hepatitis B virus life cycle in an in vitro rep locative system[J]. Antivir Chem Chem other,2002,13(6):371.
[81]DANDO T M, WAGSTAFF A J. Emtricitabine/tenofovir disop roxil fumarate[J]. Drugs,2004,64(18):2075.
[82]舒欣,李刚,姚集鲁.拉米夫定治疗乙型肝炎耐药性的产生及YMDD变异的研究[J].国外医学内科学分册,2000,27(7)：302.
[83]LAI C L.EUNG N W Y.TEO E K,et al. Results of a one-yearinternational phase II B comparative trial of telbivudine,lamivudine,and the combination,in patients with chronic hepatitis B [J].Hepatology,2003,38 (Suppl 1):262A.
[84]蔡军,熊玉卿.抗乙型肝炎病毒创新药物的研究进展[J].医药导报2009,28(1)：86.
[85]HADZIYANN IS S J.TASSOPOULOS N C,HEATHCOTE E J,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years[J]. Gastroenterology,2006,131(6):1743.
[86]Liu P,Hu YY,Liu C H,et al. Effects of salvianolic acid A (SA-A) on liver injury:SA-A action of hepatic peroxidation [J].Liver,2001,21:384.
[87]TEMNNEY D J.Hepatitis B virus resistance to entecavir involves novel changes in the viral polymerase [J].Hepatology,2004,40(4Supp 111):245A.
[88]QAQ ISH R B, MARRES K A, R ITCH IE D J. Adefovir dip ivoxil:a new antiviral agent for the treatment of hepatitis B virus infection[J].Clin Ther,2003,25(12):3084.
[1]袁永兵,张兰珍,郭亚建,等.RP-HPLC法测定叶下珠中没食子酸、柯里拉京和鞣花酸的含量[J].北京中医药大学学报,2009,32(1)：56-58.
[2]彭立志,贺劲松,童光东,等.叶下珠提取物抗乙肝病毒及乙肝病毒X基因的研究[J].中西医结合肝病杂志,2006,16(6)：340-343.
[3]谢志春.叶下珠抗乙肝病毒作用的研究现状[J].广西医学,2006,28(2)：164-166.
[4]张芝英.高效液相色谱法测定叶下珠中没食子酸的含量[J].中国药业,2002,11(7)：53.
[5]李家珉.叶下珠中抗PA1-1成分柯里拉京的提取分离[D].广州中医药大学,2009,广州.
[6]沈志强,陈蓬,段理,等.叶下珠有效部位对凝血系统的影响[J].中草药,2004,35(5)：539-542.
[7]窦志芳,冯前进,闫娟丽,等.苦味叶下珠抗病毒作用的研究进展[J].中华中医药期刊,2007,25(11)：2311-2312.
[8]李兰岚,范适,饶立群,等.叶下珠提取物对体外四氯化碳损伤肝细胞的保护作用[J].中国组织工程与临床康复,2007,11(25)：4909-4912.
[9]冀德富,郭冬艳,裴妙荣.叶下珠总多酚提取工艺的优选[J].山西中医学院学报,2010,11(1)：16-18.
[10]肖凯,宣利江,徐亚明,等.虎杖的化学成分研究[J].中国药学杂志,2003,38(1)：12-15.
[11]莫志贤,邵红霞.白藜芦醇苷体外对过氧化氢导致小鼠肝细胞损伤的保护作用[J].中国药理学通报,2000,16(5)：519-521.
[12]张霖,陈育尧,孙学刚,等.虎杖苷对非酒精性脂肪肝大鼠保护作用及机制研究[J].陕西中医,2010,31(6)：756-758.
[13]杨溪琳.虎杖的现代药用研究[J].中国社区医师,2008,10(1)：24.
[14]陈文霞,谈献和,李伟,等.白花蛇舌草]-IPLC指纹图谱的研究[J].现代中药研究与实践,2006,20：38-40.
[15]谭宁华,王双明,杨亚滨,等.白花蛇舌草抗肿瘤活性和初化学研究[J].天然产物研究与开发,2004,14(5)：33-36.
[16]赵浩如,李瑞,林以宁,等.白花蛇舌草不同提取工艺对抗肿瘤活性的影响[J].中国药科大学学报,2002,33(6)：510.
[17]张硕,宋衍芹,倪同尚,等.白花蛇舌草总黄酮抑制人肝癌细胞的靶基因调控[J].世界华人消化杂志,2007,15(10)：1060-1066.
[18]陈秀珍,朱大诚,王艳辉.白花蛇舌草药理作用及临床应用研究进展[J].中药材,2009,32(1)：157-160.
[19]阮金兰,赵钟样,曾庆忠.赤芍化学成分和药理作用的研究进展[J].中国药理学通报,2003,19 (9)：965-970.
[20]陈晓宇,宗云奎.三种中草药及其复方体外对HBsAg、HBeAg分泌的抑制[J].中国药物与临床,2002,2(1)：46-48.
[21]黄桢.黄芪多糖的药理研究进展[J].中国临床医药学杂志,2002,11(5)：315.
[22]王淑华,王红霞.浅析黄芪不同剂量的药理作用[J].浙江中医杂志,2002(6)：260.
[23]侯双,杨艳芳,魏建和,等.丹参有效成分合成积累及调控的分子机制研究进展[J].现代中药研究与实践,2010,24(4)：82-85.
[24]刘艾林,李铭源,王一涛,等.丹参药理学活性物质基础研究现状[J].中国药学杂志,2007,42(9)：641-646.
[25]辜海英,钟森,陈红苹.复方丹参注射液治疗慢性乙型肝炎的荟萃分析[J].现代中西医结合杂志,2009,18(16)：1851.
[26]沙飞,禹志领,王一涛.土茯苓品质与药理研究进展[J].中药材,2006,29(5)：516-519.
[27]曾惠芳,苏子仁,史俏蓉,等.虎杖单煎、复方共煎过程中的物理化学变化初探[J].中国药房,1999,10(3)：112-113.
[28]苏子仁,曾惠芳,史俏蓉.虎杖提取工艺初探[J].中国实验方剂学杂志,1998,24(11)：671.
[29]陆汉军,白凝凝.虎杖解毒汤治疗急性乙型病毒性肝炎128例[J].辽宁中医杂志,2001,28(7)：415.
[30]艾绍佐.以虎杖为主治甲型肝炎初探[J].中国民族民间医药杂志,2002,58：273.
[31]王志洁,程仲敏,方学韫.虎杖、黄芪联用抗I型疱疹病毒药效分析[J].中国中药杂志,1999,24(3)：176-181.
[32]陈英利,刑杰,吕跃山,等.黄芪、赤芍对小鼠免疫性肝损伤的保护作用[J].贵阳医学院学报,2008,33(4)：357-359.
[33]黄浩,周琳,姜标.丹参-赤芍配伍的化学成分动态变化研究[J].世界科学技术-中医药现代化·基础研究,2005,7(4)：18-23.